Comprehensive analysis of the role of the PGRN and its associated signalling axes, particularly in the context of GBM and the possibility of its modulation with drugs and immunomodulatory treatments may bring tangible benefits associated with understanding this type of tumour and the possibility of comprehensive influence exerted on the immune response in order to obtain superior clinical results. The gene discussed is GRN; the disease is glioblastoma.